PX1 Research provides verified, analytical-grade Sermorelin / GHRP-2 peptide blends formulated specifically for laboratory research use only. Every batch undergoes rigorous ISO 17025 analytical testing to ensure sequence integrity, ultra-high purity, and strict endotoxin compliance. Explore dual-pathway pituitary signaling and receptor co-activation models with fully traceable research compounds.
PX1 Research provides verified, analytical-grade Sermorelin / GHRP-2 peptide blends formulated specifically for laboratory research use only. Every batch undergoes rigorous ISO 17025 analytical testing to ensure sequence integrity, ultra-high purity, and strict endotoxin compliance. Explore dual-pathway pituitary signaling and receptor co-activation models with fully traceable research compounds.
To buy sermorelin ghrp-2 blend peptide for in vitro or animal models, laboratory researchers require analytical-grade compounds with guaranteed sequence fidelity, ultra-high purity, and verified low endotoxin levels. PX1 Research supplies USA-manufactured sermorelin and GHRP-2 pre-mixed research lyophilisate, complete with lot-specific mass spectrometry (MS) and high-performance liquid chromatography (HPLC) certificates of analysis.
When evaluating a qualified vendor to buy sermorelin ghrp-2 blend peptide, research institutions prioritize supplier transparency, consistent lyophilisate cake structure, rapid domestic fulfillment, and comprehensive lot traceability. PX1 Research fulfills these requirements by manufacturing within GMP-compliant domestic facilities and shipping directly from California and Arizona distribution hubs with same-day dispatch for orders placed Monday through Friday.
The combination of Sermorelin acetate and GHRP-2 (Growth Hormone Releasing Peptide-2) represents a dual-agonist experimental model designed to investigate synergistic somatotropic signaling. Sermorelin is a synthetic 29-amino-acid peptide representing the N-terminal functional fragment of endogenous Growth Hormone-Releasing Hormone, GRF(1-29)-NH2. It acts as a selective reference agonist for the GHRH receptor (GHRH-R) located on pituitary somatotropes. Binding to GHRH-R stimulates the Gs alpha subunit, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA) pathways.
In contrast, GHRP-2 (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide that targets the Growth Hormone Secretagogue Receptor (GHS-R1a), also known as the ghrelin receptor. Activation of GHS-R1a operates via a distinct G-protein coupled cascade (Gq/11), triggering phospholipase C (PLC) activity, inositol trisphosphate (IP3) generation, and transient intracellular calcium influx. Preclinical studies suggest that simultaneously targeting both GHRH-R and GHS-R1a produces a non-linear, complementary intracellular signal amplification, yielding greater somatotrope depolarization and exocytosis than isolated receptor stimulation.
As a truncated derivative of full-length GHRH(1-44), Sermorelin retains the complete biological activity and receptor affinity of the native hypothalamic peptide while offering improved solid-phase synthesis yields and terminal stability. In vitro binding assays demonstrate that the primary 29-amino-acid sequence contains all the requisite contacts for ligand-binding domain engagement on the extracellular loops of GHRH-R.
In cell culture and mammalian tissue models, Sermorelin serves as a foundational benchmark for physiological somatotrope signaling. Because GHRH-R signaling is modulated by endogenous somatostatin (SRIF) feedback loops, Sermorelin preserves native pulsatile growth hormone expression dynamics in preclinical studies. Researchers studying peptide structure-activity relationships frequently utilize sermorelin to analyze receptor desensitization kinetics, receptor internalization rates, and downstream gene transcription downstream of cAMP response element-binding protein (CREB).
GHRP-2 is recognized in the literature as one of the most potent synthetic ghrelin mimetics in the growth hormone secretagogue class. Structurally engineered to resist enzymatic cleavage by ubiquitous plasma peptidases (such as dipeptidyl peptidase-IV and neutral endopeptidase), GHRP-2 demonstrates superior metabolic half-life in extracellular media compared to native ghrelin.
When evaluated in isolated pituitary cell cultures, ghrp-2 stimulates robust, dose-dependent growth hormone release without disrupting basal thyroid-stimulating hormone (TSH) or luteinizing hormone (LH) expression. However, because GHS-R1a receptors are also expressed across hypothalamic regions regulating appetite and adrenal axes, preclinical animal models investigating GHRP-2 often monitor secondary signaling markers, including mild elevations in ACTH and cortisol, alongside feeding behavior responses.
To select the appropriate experimental matrix, investigators frequently evaluate how the Sermorelin / GHRP-2 combination compares against other GHRH analogs and ghrelin receptor agonists available in our all peptides library. The primary operational distinctions center around binding affinity, half-life modifications, and receptor selectivity profiles across different synthetic classes.
For example, while Sermorelin features a native-like short plasma half-life suitable for acute pulsatile signaling assays, modified tetrasubstituted analogs such as cjc-1295-no-dac incorporate specific amino acid substitutions (e.g., D-Ala2, Gln8, Ala15, Leu27) that enhance plasma protein binding and enzymatic resistance. On the secretagogue arm, while GHRP-2 offers potent GHS-R1a activation with modest adrenal axis co-stimulation, selective non-opioid peptides like ipamorelin exhibit heightened selectivity for GHS-R1a without stimulating ACTH or prolactin secretion. Choosing between a Sermorelin / GHRP-2 blend and alternative pairings like CJC-1295 / Ipamorelin depends primarily on whether the research framework requires maximum peak amplitude signaling or highly selective, isolated somatotrope responses.
Literature evaluating dual GHRH-R and GHS-R1a co-activation spans several decades of neuroendocrine and metabolic research. Early rodent models established that co-administration of a GHRH agonist with a synthetic GHRP produced a synergistic pituitary response far exceeding the simple mathematical sum of individual peptide actions. In vitro perifusion models of rat anterior pituitary cells confirmed that this synergy relies on cross-talk between the cAMP/PKA and IP3/DAG intracellular cascades.
Current academic research utilizing dual-agonist blends focuses on age-related somatopause signaling models, muscle wasting pathogenesis, bone density regulation, and neuroprotective pathways. To examine comprehensive physiological data across secretagogue classes, researchers can review our dedicated growth hormone secretagogues overview in the PX1 research portal.
Proper reconstitution technique is critical to maintain structural integrity, prevent aggregation, and ensure reproducible molar ratios when working with blended lyophilized peptides. Researchers should perform all liquid handling within a certified Class II laminar flow biosafety cabinet using aseptic technique.
Prior to handling, centrifuge the vial briefly at low speed (1000–2000 x g) to consolidate the lyophilized cake at the bottom of the glass container. Slowly introduce an appropriate volume of sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline down the inner glass wall of the vial. Avoid directing the solvent stream directly onto the peptide cake. Allow the solvent to wick naturally into the powder matrix, then gently swirl the vial in a circular motion. Never vortex or vigorously shake peptide solutions, as mechanical shear stress can disrupt secondary protein structures and promote aggregation. For step-by-step volumetric calculations, consult our interactive peptide reconstitution calculator guide.
Lyophilized Sermorelin / GHRP-2 blends supplied by PX1 Research exhibit high solubility in aqueous buffer systems maintained near neutral pH (pH 6.0–7.4). If preparing concentrated stock solutions for specific in vitro microfluidic or cell culture assays, researchers may utilize sterile phosphate-buffered saline (PBS) or dilute acetic acid (0.1 M) if initial solubilization requires pH adjustment.
Unreconstituted lyophilized vials should be stored in a controlled freezer environment at -20°C or -80°C, protected from light and moisture desiccation. Under these cold-storage conditions, the dried peptide matrix remains stable for up to 24 months. Once reconstituted, liquid aliquots should be divided into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles. Reconstituted aqueous solutions stored at 2°C to 8°C should be utilized within 14 to 28 days depending on the preservative used.
Quality assurance is paramount when sourcing research peptides for quantitative scientific studies. PX1 Research tests every production lot of Sermorelin / GHRP-2 blend through independent, ISO 17025-accredited analytical laboratories to verify chemical composition, purity, and safety profiles.
Purity is assessed using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) with ultraviolet detection. The resultant chromatogram must confirm total peptide purity exceeding 99.0%, with discrete, sharp peak resolution for both Sermorelin and GHRP-2 components. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms the precise molecular weight of both active peptide species down to atomic mass units. Furthermore, because bacterial endotoxins can confound cell culture viability and induce artifactual inflammatory responses in animal models, PX1 Research enforces stringent chromogenic LAL testing to ensure endotoxin content remains strictly below <0.01 EU/mg.
PX1 Research is dedicated to supporting academic institutions, pharmaceutical laboratories, and biotechnology firms with reliable peptide manufacturing and rapid fulfillment. All compounds are synthesized in state-of-the-art domestic facilities adhering to strict GMP compliance protocols.
Principal investigators and laboratory procurement officers seeking custom batch sizes, bulk volumetric pricing, or specialized analytical documentation can request access through our dedicated wholesale laboratory accounts portal. Additional technical documentation, validation studies, and scientific articles are available within our central research library.
What is the primary mechanism of a Sermorelin / GHRP-2 blend?
The blend combines a GHRH-R reference agonist (Sermorelin) with a GHS-R1a ghrelin receptor agonist (GHRP-2). In preclinical models, simultaneous stimulation of both receptor pathways produces synergistic intracellular signaling (cAMP/PKA + IP3/DAG), resulting in enhanced growth hormone exocytosis compared to either peptide alone.
What purity levels are guaranteed for PX1 Research peptide blends?
PX1 Research guarantees a overall peptide purity of ≥99.0% as determined by lot-specific Reverse-Phase HPLC. Identity is independently verified via Mass Spectrometry (ESI-MS).
How is endotoxin content validated for this compound?
Every lot undergoes quantitative chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels are maintained below <0.01 EU/mg, preventing cellular toxicity or artifactual inflammatory responses in experimental models.
What reconstituting diluents are recommended for laboratory use?
Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride injection solution are standard reconstitution diluents. For long-term cell culture applications requiring preservative-free media, sterile phosphate-buffered saline (PBS) or sterile water for injection may be used.
How should reconstituted Sermorelin / GHRP-2 solutions be stored?
Reconstituted liquid solutions should be kept refrigerated at 2°C to 8°C and used within 14–28 days. To store for longer periods, freeze liquid aliquots immediately at -20°C or -80°C to eliminate damage from repeated freeze-thaw cycles.
Where does PX1 Research ship from and what are the handling times?
All orders ship directly from PX1 Research fulfillment facilities located in California and Arizona. Orders placed Monday through Friday before cut-off times are dispatched same-day in temperature-controlled, protective packaging.
Can Sermorelin / GHRP-2 blend be used in human subjects or clinical settings?
No. Products sold by PX1 Research are strictly intended for laboratory in vitro and preclinical animal research use only. They are not intended for human or veterinary medical use, therapy, injection, or direct administration.
How does GHRP-2 differ from GHRP-6 in preclinical research?
GHRP-2 exhibits higher binding affinity for GHS-R1a and stronger growth hormone releasing potency than GHRP-6 in vitro. However, GHRP-6 exhibits a stronger stimulation of orexigenic (appetite) pathways and less selectivity relative to adrenal axis co-stimulation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.